Strong financial results and R&D investment for Chiesi Group

CHIESI Group has announced strong financial and sustainability results for 2025.

The Italy-based group, whose UK head office is in Manchester, reported €3.6 billion in revenue, up 8.2%.

It reinforced its commitment to innovation, sustainability, and patient-centric care, backed by record €885m R&D investment, and  confirmed its B Corp recertification, plus progress on low-carbon inhaler technology.

Chiesi Group confirmed its CEO Giuseppe Accogli will step down in May, and its Chief Financial Officer – Jean-Marc Bellemin – will assume the role of Interim CEO, in a transition designed to maintain momentum.

In March Chiesi Group and Bespak announced an expansion of their partnership to increase UK pressurised metered dose inhaler manufacturing capacity, at the Holmes Chapel, Cheshire, Bespak site.